Drug Target Review2024-11-28T08:00:42
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-03T12:09:00Z
2026-11-02T14:33:00Z
Sponsored by Integra Biosciences
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., Drug Target Review
2023-03-03T14:06:14
Sponsored by Bio-Techne
2026-08-24T08:43:00
Author Dr Dana Watt
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2024-01-26T13:22:42
Sponsored by bit.bio
Site powered by Webvision Cloud